Stryker Completes Acquisition of Inari Medical, Enhancing Vascular Segment

Stryker, a leader in medical technologies, has completed its acquisition of Inari Medical, Inc., an innovator in venous thromboembolism (VTE) solutions, marking a significant expansion into the high-growth peripheral vascular segment. The acquisition, completed on February 19, 2025, allows Stryker to strengthen its interventional endovascular portfolio and aligns with its broader strategic goals. With the acquisition, Inari becomes a wholly owned subsidiary of Stryker. Previously, a cash tender offer of $80.00 per share was made for outstanding shares of Inari Medical, and upon acceptance, the merger was finalized. This move positions Stryker to effectively enhance its Neurovascular business with Inari’s thrombectomy systems, FlowTriever and ClotTriever, catering to pulmonary embolism and peripheral vessel thrombectomy, respectively. The merger is viewed as an opportunity to utilize Inari’s established position and emerging therapies in the vascular segment to further elevate patient outcomes worldwide.